Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.

Jin Matsuyama,Hisato Kawakami,Kazumasa Fujitani,Yusuke Akamaru,Shigeyuki Tamura,Shunji Endo,Yutaka Kimura,Youichi Makari,Takao Tamura,Naotoshi Sugimoto,Daisuke Sakai,Toshimasa Tsujinaka,Masahiro Goto,Yukinori Kurokawa,Toshio Shimokawa,Taroh Satoh

Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.

2020

Jin Matsuyama
Hisato Kawakami
Kazumasa Fujitani
Yusuke Akamaru
Shigeyuki Tamura
Shunji Endo
Yutaka Kimura
Youichi Makari
Takao Tamura
Naotoshi Sugimoto
Daisuke Sakai
Toshimasa Tsujinaka
Masahiro Goto
Yukinori Kurokawa
Toshio Shimokawa
Taroh Satoh

379Background: HERBIS-2 trial was a phase II trial where S-1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) were compared in recurrent HER2 negative gastric cancer (GC) patients with recu...

Keywords:

Cancer
Internal medicine
Adjuvant therapy
Medicine
Chemotherapy
Cisplatin
Oncology
Recurrent gastric cancer
Capecitabine
HER2 negative
Pathology
in patient
pooled analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations